Q. Thiéblemont

Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.

D. Johns, T. Sulpice, F. Briand, 2014, European journal of pharmacology.

Upregulating Reverse Cholesterol Transport With Cholesteryl Ester Transfer Protein Inhibition Requires Combination With the LDL-Lowering Drug Berberine in Dyslipidemic Hamsters

T. Sulpice, F. Briand, E. Muzotte, 2013, Arteriosclerosis, thrombosis, and vascular biology.

High-fat and fructose intake induces insulin resistance, dyslipidemia, and liver steatosis and alters in vivo macrophage-to-feces reverse cholesterol transport in hamsters.

T. Sulpice, F. Briand, E. Muzotte, 2012, The Journal of nutrition.

Raising HDL with CETP inhibitor torcetrapib improves glucose homeostasis in dyslipidemic and insulin resistant hamsters.

T. Sulpice, S. Sordello, F. Briand, 2014, Atherosclerosis.

Sitagliptin promotes macrophage‐to‐faeces reverse cholesterol transport through reduced intestinal cholesterol absorption in obese insulin resistant CETP‐apoB100 transgenic mice

R. Burcelin, T. Sulpice, F. Briand, 2012, Diabetes, obesity & metabolism.

CETP Inhibitor Torcetrapib Promotes Reverse Cholesterol Transport in Obese Insulin‐Resistant CETP‐ApoB100 Transgenic Mice

T. Sulpice, K. Ouguerram, F. Briand, 2011, Clinical and translational science.

Upregulating Reverse Cholesterol Transport With Cholesteryl Ester Transfer Protein Inhibition Requires Combination With the LDL-Lowering Drug Berberine in Dyslipidemic Hamsters

T. Sulpice, F. Briand, E. Muzotte, 2013, Arteriosclerosis, thrombosis, and vascular biology.